A novel hepatitis B treatment has demonstrated unprecedented efficacy, functionally curing nearly one-fifth of trial participants and signaling a shift toward immune-based therapies. At the same time, concerns over space industry stability and research funding underscore the fragile balance between innovation and institutional support. These developments reflect urgent debates about public trust, ethical boundaries, and the future of scientific progress.
Bluesky
#medical innovation
#public health
#scientific research
#space industry
